ENvue Medical wins USPTO notice of allowance for ultrasound-enhanced cannabinoid delivery patent

ENvue Medical, Inc.

ENvue Medical, Inc.

FEED

0.00
  • ENvue Medical said USPTO issued Notice of Allowance for U.S. Patent Application No. 17/025,969 covering surface acoustic wave ultrasound technology designed to enhance transdermal delivery of cannabinoid-based therapeutics.
  • Claims cover system components such as patch configurations, portable SAW-generating platforms, plus related delivery methods.
  • Company framed allowance as expanding its SAW platform beyond current products, with potential for future partnerships in cannabinoid-focused treatment areas.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Envue Medical Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202605080915PRIMZONEFULLFEED9716215) on May 08, 2026, and is solely responsible for the information contained therein.

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.